Marblegate Acquisition's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Marblegate Acquisition (GATE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Marblegate Acquisition's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Marblegate Acquisition Corp | - | - | - | No |
| Competitors combined (1) | ||||
| High-Confidence Competitors (3) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GATE Stock Performance relative to its Competitors
GATE Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Heron Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Marblegate Acquisition's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Marblegate Acquisition's Comment on Competition and Industry Peers
Publicly Traded Peers of Marblegate Acquisition Corp
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Marblegate Acquisition Corp |
431.61 | - |
 Heron Therapeutics Inc |
66.55 | 149.46 |
| SUBTOTAL | 498.17 | 149.46 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Marblegate Acquisition Corp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Marblegate Acquisition's Competitors Named by the Company
Competitive relationships identified from Marblegate Acquisition reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| MTA | Company report | 85% |
| Citi Bike | Company report | 85% |
| Signal Taxi | Company report | 85% |
| Lyft | Company report | 85% |
| Uber | Company report | 85% |
Company report basis, confidence, active dates and source counts for Marblegate Acquisition's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Marblegate Acquisition's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Marblegate Acquisition Corp | 432 | - | - |
| Heron Therapeutics Inc | 67 | 1,167,641 | -168,438 |
| PEERS TOTAL | 67 | 1,167,641 | -168,438 |
Marblegate Acquisition's Position in Industry Market Structure
Market-capitalization share and concentration across all 175 companies in Marblegate Acquisition's industry classification, broader than the peer set above. Market cap in millions of $.Marblegate Acquisition ranks #0 of 175 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 117, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Dutch Oven Gold Group Inc | 1,595 | 5.45 % |
| 2 | Jaws Mustang Acquisition Corporation | 940 | 3.21 % |
| 3 | Constellation Acquisition Corp I | 677 | 2.31 % |
| 4 | Drugs Made In America Acquisition Ii Corp | 513 | 1.75 % |
| 5 | Cantor Equity Partners Iv Inc | 1,234 | 5.2% |
| 6 | Mntn Inc | 1,234 | 5.2% |
| 7 | Sound Point Acquisition Corp I Ltd | 1,234 | 5.2% |
| 8 | Aldel Financial Ii inc | 1,234 | 5.2% |
| 9 | Gores Holdings X Inc | 1,234 | 5.2% |
| 10 | American Exceptionalism Acquisition Corp A | 1,234 | 5.2% |
| 0 | Marblegate Acquisition Corp | 432 | 0.00 % |
Market cap and industry share for the rest of Marblegate Acquisition's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-04-06.
Marblegate Acquisition's Valuation vs Competitive Position
Valuation multiples vs the Blank Checks industry average (65 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Blank Checks industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 46.1x | - |
| EV / EBITDA | - | 22.3x | - |
| P/B | -5.7x | 6.8x | -12.6x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -2.58 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Marblegate Acquisition's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue Growth | - | - | - | - |
| Operating Margin | - | - | - | - |
| Return on Invested Capital | - | -0.78 % | - | - |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Marblegate Acquisition's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 117 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Marblegate Acquisition's dedicated Suppliers and Customers pages, not here.
Marblegate Acquisition's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
No rule matched.
Opportunities
- Industry revenue growing at a healthy 26.9% median pace.
- A meaningful share of competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Marblegate Acquisition's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Marblegate Acquisition Corp | 0.16 | 0.25 | - |
| Heron Therapeutics Inc | 0.30 | 2.46 | 3.81 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Marblegate Acquisition's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Marblegate Acquisition Corp | Q4 2024 | - | - |
| Heron Therapeutics Inc | Q3 2026 | -5.5 % | - |
| PEERS TOTAL | -5.5 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Marblegate Acquisition's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Marblegate Acquisition Corp | Q4 2024 | - | - |
| Heron Therapeutics Inc | Q3 2026 | -18.6 % | - |
Marblegate Acquisition's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Marblegate Acquisition Corp | - | - | - |
| Heron Therapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Marblegate Acquisition's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Marblegate Acquisition Corp | - | - |
| Heron Therapeutics Inc | - | 0.45 |
| PEERS AVERAGE | - | 3.33 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.